NEW YORK (GenomeWeb News) – The US Food and Drug Administration has told 23andMe that it must stop marketing its spit test and genome service to consumers because it has failed to address FDA's questions about the clinical and analytical validity of the product.

In a letter sent to company CEO Anne Wojcicki on Friday, the FDA said 23andMe must cease marketing the Saliva Collection Kit and Personal Genome Service to consumers immediately, and may not start marketing it again until it has received the agency's authorization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.